Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Marker Therapeutics, Inc. (MRKR)
|
Add to portfolio |
|
|
|
| Price: |
$0.98
| | Metrics |
| OS: |
8.81
|
M
| |
|
|
| Market cap: |
$8.63
|
M
| |
|
|
|
Net cash:
|
$18.1
|
M
| |
$2.06
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($23.4)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 9.0 | 1.2 | 0.5 | 0.2 | 0.2 | 0.2 | 0.2 | 0.0 |
| Revenue growth | 625.9% | 166.0% | 118.9% | 3.5% | 12.5% | -8.5% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 |
| Gross profit | 9.0 | 1.2 | 0.5 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 26.1 | 27.8 | 18.9 | 12.8 | 8.0 | 5.3 | 3.8 | 1.7 |
| General and administrative | 12.8 | 12.9 | 10.5 | 10.0 | 24.4 | 6.4 | 4.7 | 4.4 |
| EBIT | -30.2 | -41.9 | -28.9 | -22.5 | -148.2 | -11.5 | -8.5 | -6.2 |
| EBIT margin | -334.8% | -3373.1% | -6188.2% | -10567.3% | -71930.1% | -6271.1% | -4246.1% | |
| Pre-tax income | -29.9 | -41.9 | -28.7 | -21.4 | -148.0 | -11.0 | -2.5 | -34.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -29.9 | -41.9 | -28.7 | -21.4 | -148.0 | -11.0 | -2.5 | -34.1 |
| Net margin | -332.1% | -3372.7% | -6149.7% | -10050.9% | -71826.3% | -5999.1% | -1227.7% | |
| |
| Diluted EPS | ($3.58) | ($5.47) | ($0.61) | ($0.47) | ($7.75) | ($1.16) | ($0.33) | ($9.30) |
| Shares outstanding (diluted) | 8.4 | 7.7 | 47.0 | 45.6 | 19.1 | 9.5 | 7.4 | 3.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|